Zobrazeno 1 - 10
of 255
pro vyhledávání: '"A. T. Van Oosterom"'
Autor:
G. Huygh, Paul M. J. Clement, H. Dumez, P. Schöffski, H. Wildiers, J. Selleslach, J. M. Jimeno, I. De Wever, R. Sciot, L. Duck, A. T. Van Oosterom
Publikováno v:
Sarcoma, Vol 2006 (2006)
Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a d
Externí odkaz:
https://doaj.org/article/cabcf7f9911a4f30932b09167f5efa9c
Publikováno v:
Sarcoma, Vol 6, Iss 4, Pp 135-139 (2002)
We report the case of a 66-year-old man presenting with a high-grade pleomorphic sarcoma at the left elbow 16 years after the extravasation of adriamycin given for a malignant ifbrous histiocytoma of the tibia.We suggest that this sarcoma originated
Externí odkaz:
https://doaj.org/article/ce3a70d3e86041b69c250d3154a3434b
Publikováno v:
Techniques in coloproctology, 24(6), 593-597. Springer-Verlag Italia
Background: The aim of this study was to evaluate the efficacy of a combination of flaps for the reconstruction of presacral defects following abdominoperineal resections: a paramedian vertically oriented caudally based lotus petal flap for presacral
Autor:
Patrick Schöffski, Scott M. Schuetze, S. McCoy, Binh Bui, Daniel E. Stepan, Jean-Yves Blay, Yu Nien Sun, Allan T. van Oosterom, Robert S. Benjamin, Lee S. Rosen, Jörg T. Hartmann, Laurence H. Baker, Peter Reichardt, Keith M. Skubitz, Justus Duyster
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This multicenter phase 2 study assessed the tolerability and efficacy of motesanib, an oral inhibitor of Kit, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptors (VEGFR), in patients with imatinib
Autor:
Herlinde Dumez, Agnieszka Wozniak, Jose Jimeno, C Stefan, Pascal Wolter, Patrick Schöffski, Allan T. van Oosterom
Publikováno v:
Expert Opinion on Pharmacotherapy. 9:1609-1618
Patients with advanced or metastatic non-gastrointestinal stromal tumour soft tissue sarcoma (STS) whose disease progresses during or after chemotherapy with doxorubicin or ifosfamide have few options and very limited life expectancy. In this setting
Autor:
Michael Heinrich, Denis Soulières, Zariana Nikolova, Jonathan A. Fletcher, Stephan Dirnhofer, and Grant McArthur, Shane G. Supple, Ajia Town, John F. Seymour, Heikki Joensuu, Allan T. van Oosterom, George D. Demetri, Jane F. Apperley, Amy Harlow, Arin McKinley, Lilla Di Scala, Christopher L. Corless, Richard Herrmann
Publikováno v:
Clinical Cancer Research. 14:2717-2725
Purpose: To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases. Experimental Design: This was a phase II, open-label, single arm study. Patients ≥15 years
Autor:
Ernst A. de Bruijn, Gunter Guetens, Allan T. van Oosterom, Marc Martens, Robert A. A. Maes, J. Selleslach, Rita Aerts, Herlinde Dumez, Gert De Boeck
Publikováno v:
Anti-Cancer Drugs. 18:211-218
Our objective was to determine the response to gemcitabine plus docetaxel in advanced urothelial transitional cell carcinoma in a phase II trial, and gemcitabine distribution between plasma and erythrocytes, following docetaxel administration. Patien
Autor:
Janine Mansi, Ernst A. de Bruijn, Gunther Guetens, Robert A. A. Maes, G. Momerency, Hans Prenen, Allan T. van Oosterom, Peter Blake, Tim Mant, Peter Harper, Gert De Boeck, Diane Sawyers, M.S. Highley
Publikováno v:
Journal of Analytical Oncology. 4
Purpose : Ifosfamide can cause an unexplained encephalopathy. The incidence after intravenous infusion is 10%, but is much higher after oral administration. This study assesses the pharmacokinetics of oral ifosfamide in relation to neurotoxicity. Pat
Publikováno v:
Sports Injuries ISBN: 9783642365683
Sports Injuries ISBN: 9783642368011
Sports Injuries ISBN: 9783642368011
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07613a8e1d5f2210c44d92dd1c6670cd
https://doi.org/10.1007/978-3-642-36569-0_259
https://doi.org/10.1007/978-3-642-36569-0_259
Autor:
Jean-Yves Blay, Rolf D. Issels, Peter Reichardt, Allan T. van Oosterom, Axel Le Cesne, Ian Judson, John Simes, Jaap Verweij, Martine Van Glabbeke, Paolo G. Casali
Publikováno v:
European Journal of Cancer. 42:2277-2285
The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation betw